Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working …
TW Synold, CH Takimoto, JH Doroshow, D Gandara… - Clinical cancer …, 2007 - AACR
Purpose: To determine the toxicities, pharmacokinetics, and maximally tolerated doses of
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for …
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for …
[引用][C] Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ …
TW Synold, CH Takimoto, JH Doroshow… - Clinical Cancer …, 2007 - cir.nii.ac.jp
Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired
Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study | CiNii …
Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study | CiNii …
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working …
TW Synold, CH Takimoto… - … : an official journal …, 2007 - pubmed.ncbi.nlm.nih.gov
Purpose To determine the toxicities, pharmacokinetics, and maximally tolerated doses of
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for …
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for …
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: A national cancer institute organ dysfunction working …
TW Synold, CH Takimoto… - Clinical Cancer …, 2007 - einstein.elsevierpure.com
Purpose: To determine the toxicities, pharmacokinetics, and maximally tolerated doses of
oxaliplatin in patientswith hepaticimpairment and to develop formal guidelines for oxaliplatin …
oxaliplatin in patientswith hepaticimpairment and to develop formal guidelines for oxaliplatin …
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working …
TW Synold, CH Takimoto, JH Doroshow… - … Cancer Research: an …, 2007 - europepmc.org
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired
hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. - Abstract …
hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. - Abstract …
[引用][C] Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: A national cancer institute organ dysfunction …
TW SYNOLD, CH TAKIMOTO, HJ LENZ… - Clinical cancer …, 2007 - pascal-francis.inist.fr
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired
hepatic function : A national cancer institute organ dysfunction working group study CNRS …
hepatic function : A national cancer institute organ dysfunction working group study CNRS …
[PDF][PDF] Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ …
SC Remick, DL Mulkerin, A Hamilton, S Sharma… - Clin Cancer …, 2007 - researchgate.net
Purpose: To determine the toxicities, pharmacokinetics, and maximally tolerated doses of
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for …
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for …
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: A national cancer institute organ dysfunction working …
TW Synold, CH Takimoto… - Clinical Cancer …, 2007 - mayoclinic.elsevierpure.com
Purpose: To determine the toxicities, pharmacokinetics, and maximally tolerated doses of
oxaliplatin in patientswith hepaticimpairment and to develop formal guidelines for oxaliplatin …
oxaliplatin in patientswith hepaticimpairment and to develop formal guidelines for oxaliplatin …
[PDF][PDF] Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ …
SC Remick, DL Mulkerin, A Hamilton, S Sharma… - Clin Cancer …, 2007 - academia.edu
Purpose: To determine the toxicities, pharmacokinetics, and maximally tolerated doses of
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for …
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for …